Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Flavonoids of Lysimachia christinae Capsules for Residual Stones After PCNL
ChiCTR2500109693Phase 4Not yet recruiting
- Sponsor
- Beijing Tsinghua Changgung Hospital
- Start
- Dec 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of total flavonoids of Lysimachia christinae capsules in Lithiasis and nephrolithiasis (2 arms), sponsored by Beijing Tsinghua Changgung Hospital. Primary endpoint: 12-week postoperative stone-free rate. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
total flavonoids of Lysimachia christinae capsules
03
Conditions
Lithiasisnephrolithiasis
Beyond the preview
Go deeper on ChiCTR2500109693.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500109693.